Yang
88 IP cases indexed. Covers patent matters.
Cases Presided Over
88 cases indexed | Page 3 of 3
QIAGEN Sciences, LLC v.Tecan Group AG
Tecan Group AG seeks Director Review to overturn the PTAB’s institution of QIAGEN’s IPR, arguing that parallel petitions create inefficiency and unfairness. The request cites statutory grounds under 35 U.S.C. § 316(b) and an Acting Director memo.
Berkshire Hathaway Energy Company et al. v.MES, Inc.
Berkshire Hathaway Energy’s power subsidiaries settled with Birchtech, leading the PTAB to terminate the IPR as to those petitioners while the case remains open for the remaining parties. The settlement agreement was deemed business‑confidential.
Padagis US LLC et al. v.Neurelis, Inc.
The PTAB held that all 36 claims of Neurelis’s intranasal benzodiazepine patent are obvious over prior art references Gwozdz, Meezan ’962, and Cartt ’784, rendering the patent entirely unpatentable.
Padagis US LLC et al. v.Neurelis, Inc.
The PTAB held that all 36 claims of Neurelis’s intranasal benzodiazepine patent are obvious over a combination of prior‑art references, rendering the patent entirely unpatentable.
PacifiCorp et al. v.MES, Inc.
Utility companies and BirchTech settled multiple IPRs covering power‑grid patents. The Board treated the settlement agreements as confidential and terminated the IPRs as to the settling petitioners, leaving the remaining petitioners in the proceeding.
PacifiCorp et al. v.MES, Inc.
PacifiCorp and co-petitioners successfully challenged the '370 patent, demonstrating a reasonable likelihood of prevailing on multiple grounds of obviousness (103). The Board found that combinations of prior art references like Vosteen589/Starns or Downs-Boiler/Mass-EPA rendered key claims obvious.
PacifiCorp et al. v.MES, Inc.
The PTAB instituted IPR on PacifiCorp's claims against Birchtech Corp. regarding flue gas desulfurization technology, overcoming a time-bar defense raised by the Patent Owner. The Board found Petitioner met the reasonable likelihood standard for institution across multiple grounds of anticipation and obviousness.
PacifiCorp et al. v.MES, Inc.
The PTAB decided to institute the IPR petition against Birchtech Corp.'s '370 patent, finding that PacifiCorp et al. met the standard for reasonable likelihood of prevailing on all asserted grounds. The Board also addressed and rejected arguments from Patent Owner regarding written description and enablement issues concerning bromide compounds.
PacifiCorp et al. v.MES, Inc.
The PTAB denied institution of an IPR petition challenging a mercury removal patent (10933370) because the petitioner had filed a second, ranked petition on the same claims. The Board followed the Director's instruction to select only one petition.
Bruker Spatial Biology, Inc. v.10x Genomics, Inc. et al.
Bruker Spatial Biology and 10x Genomics settled their dispute over U.S. Patent 11,542,554, leading the PTAB to terminate the inter partes review. The settlement agreement and related documents were ordered confidential.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies challenged Tecan Genomics's NGS patent (9546399) on grounds of anticipation and obviousness over prior art references Iafrate and Kivioja. The PTAB instituted the IPR, finding a reasonable likelihood that at least one claim is unpatentable under 35 U.S.C. § 103 over Iafrate and Kivioja.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB instituted the IPR, finding a reasonable likelihood of unpatentability based on obviousness over Iafrate and Kivioja for key NGS claims. The Board also provided definitive claim constructions for 'indexing site' and 'identifier site.'
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB granted institution for an IPR challenging claims 1-16 of a nucleic acid analysis patent, finding reasonable likelihood of success. The Board rejected the Patent Owner's motion to deny based on prior art similarity, allowing the technical merits of anticipation and obviousness over Kivioja and Bielas to proceed to trial.
CSPC Pharmaceutical Group Limited et al. v.Ipsen Biopharm Ltd. et al.
The PTAB institution decision in this oncology IPR upheld the patent claims against numerous prior art references related to FOLFIRINOX and nanoliposomal irinotecan. The Board adopted a specific claim construction defining 'treatment' as requiring more than a de minimis therapeutic benefit for the patient.
SeaSpine Holdings Corporation et al. v.Jackson, Roger
The PTAB denied an IPR petition filed by SeaSpine Holdings against Roger P. Jackson because the patent owner had disclaimed all challenged claims of U.S. Patent No. 11,399,873 B2.
Inari Agriculture, Inc. v.Pioneer Hi-Bred International, Inc.
The PTAB denied institution of the PGR petition filed by Inari Agriculture against Pioneer Hi-Bred, finding that the petitioner failed to demonstrate a reasonable expectation of success. The Board specifically rejected obviousness claims because they relied on phenotypic comparisons while ignoring critical genotypic differences in maize breeding technology.
Inari Agriculture, Inc. v.Pioneer Hi-Bred International, Inc.
The PTAB denied institution of Inari Agriculture's PGR against Pioneer Hi-Bred International regarding maize breeding claims. The Board found the Petitioner failed to demonstrate a reasonable expectation of success, specifically failing to adequately address the unique genotype (PH4CYJ) central to the patent.
Inari Agriculture, Inc. v.Pioneer Hi-Bred International, Inc.
The PTAB denied Inari Agriculture's PGR challenge against Pioneer Hi-Bred International regarding maize breeding claims (1-20). The Board found the petitioner failed to demonstrate unpatentability on grounds of obviousness, utility, or indefiniteness.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s Laboratories and Eye Therapies entered a settlement that led to the joint termination of two inter partes review proceedings covering patents 11,833,245 and 11,596,600. The Board granted the termination and kept the settlement agreement confidential.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s and Eye Therapies settled their IPR dispute, resulting in a joint motion that terminated the proceedings. The Board granted the termination and kept the settlement confidential.
Nike, Inc. v.SherryWear, LLC
Nike and SherryWear settled their inter partes review of U.S. Patent 9,295,288. The Board terminated the IPR by joint motion, treating the settlement agreement as confidential.
Nike, Inc. v.SherryWear, LLC
Nike and SherryWear reached a confidential settlement, prompting the PTAB to terminate the IPRs covering SherryWear’s footwear patent (U.S. 10,219,550). The Board cited statutory authority to end the review before any merits were decided.
Nike, Inc. v.SherryWear, LLC
Nike and SherryWear reached a confidential settlement, leading the PTAB to terminate a series of inter partes reviews, including the one covering patent 10,219,551. The termination was entered under 35 U.S.C. §317 after the trials had already been instituted.
Nike, Inc. v.SherryWear, LLC et al.
Nike and SherryWear settled their IPR dispute over patent 9,808,036 B1. The Board granted a joint motion to terminate the proceedings, treating the settlement agreement as confidential.
Nike, Inc. v.SherryWear, LLC
Nike and SherryWear entered a confidential settlement, prompting the PTAB to terminate the pending IPRs, including the case involving patent 10,869,510.
PacifiCorp et al. v.MES, Inc.
Utility affiliates of Berkshire Hathaway Energy settled multiple PTAB IPRs, leading to the termination of the cases for the settling parties while the Board kept the proceedings open for the remaining petitioners.
PacifiCorp et al. v.MES, Inc.
Utility consortiums including PacifiCorp settled IPRs covering several power‑grid patents, resulting in the termination of the proceeding for two petitioners while the Board kept the case open for the remaining parties. The settlement agreement was designated business‑confidential.
PacifiCorp et al. v.MES, Inc.
MidAmerican Energy settled its IPR against BirchTech’s ’370 patent, prompting the Board to terminate the case for MidAmerican while the proceeding remains active against PacifiCorp.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.